Zacks: Brokerages Anticipate Spark Therapeutics Inc (NASDAQ:ONCE) Will Announce Quarterly Sales of $33.68 Million
Equities analysts expect that Spark Therapeutics Inc (NASDAQ:ONCE) will announce sales of $33.68 million for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Spark Therapeutics’ earnings. The lowest sales estimate is $20.30 million and the highest is $51.00 million. Spark Therapeutics reported sales of $25.19 million in the same quarter last year, which indicates a positive year over year growth rate of 33.7%. The business is scheduled to issue its next earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Spark Therapeutics will report full year sales of $130.61 million for the current fiscal year, with estimates ranging from $103.64 million to $180.70 million. For the next financial year, analysts expect that the firm will post sales of $164.50 million, with estimates ranging from $92.30 million to $264.88 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Spark Therapeutics.
Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings results on Friday, May 10th. The biotechnology company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.33). The firm had revenue of $20.77 million for the quarter, compared to analysts’ expectations of $31.20 million. Spark Therapeutics had a negative return on equity of 16.68% and a negative net margin of 124.33%.
A number of institutional investors and hedge funds have recently modified their holdings of ONCE. Aperio Group LLC increased its stake in Spark Therapeutics by 18.5% during the 2nd quarter. Aperio Group LLC now owns 7,662 shares of the biotechnology company’s stock worth $784,000 after buying an additional 1,198 shares during the period. BNP Paribas Arbitrage SA increased its stake in Spark Therapeutics by 185.2% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 20,837 shares of the biotechnology company’s stock worth $2,133,000 after buying an additional 13,531 shares during the period. Janney Montgomery Scott LLC purchased a new stake in Spark Therapeutics during the 2nd quarter worth $202,000. ARP Americas LP increased its stake in Spark Therapeutics by 41.7% during the 2nd quarter. ARP Americas LP now owns 228,617 shares of the biotechnology company’s stock worth $23,406,000 after buying an additional 67,286 shares during the period. Finally, Strs Ohio purchased a new stake in Spark Therapeutics during the 2nd quarter worth $409,000. Institutional investors own 85.26% of the company’s stock.
NASDAQ ONCE traded up $0.56 during trading hours on Thursday, hitting $99.23. 202,355 shares of the stock were exchanged, compared to its average volume of 1,154,555. The company has a market cap of $3.83 billion, a P/E ratio of -47.03 and a beta of 2.08. Spark Therapeutics has a 12-month low of $34.53 and a 12-month high of $114.20. The stock has a 50-day moving average of $99.90. The company has a current ratio of 5.94, a quick ratio of 5.59 and a debt-to-equity ratio of 0.18.
About Spark Therapeutics
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.
Read More: What is a Swap?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.